<DOC>
	<DOCNO>NCT00916552</DOCNO>
	<brief_summary>Depression bipolar disorder ( mania depression ) may relate problem nerve cell regenerate fast normal accompanied cognitive difficulty include memory , attention planning problem . There thus need good , efficient treatment effect cognitive function . Erythropoietin ( Epo ) involve brain repair may candidate future treatment strategy . The investigator demonstrate single dose Epo improve mood reduces process negative emotional information healthy volunteer similar effect see antidepressant . With current study investigator aim build upon discovery investigate whether repeat Epo administration antidepressant effect able reverse cognitive difficulty patient depression bipolar disorder . It hypothesize Epo improve mood treatment-resistant depression improve cognitive function group patient bipolar disorder remission . If study reveals beneficial effect Epo , would highlight Epo candidate compound future treatment depression bipolar disorder , potential directly promote brain repair mechanism .</brief_summary>
	<brief_title>Effects Erythropoietin Depressive Symptoms Neurocognitive Deficits Depression Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Treatmentresistant depression ( defined failure respond least 2 different type antidepressant ) HDRS score least 17 OR Bipolar disorder remission ( HDRS score max 14 Young Mania Scale score max 14 ) subjective complaint moderate severe cognitive problem Massachusetts General Hospital Cognitive Physical Functioning Questionnaire ( CPFQ ) ( Fava et al 2006 ) ( score least 4 least 2 domain ) Unchanged antidepressant mood stabilize treatment least 2 week prior study Schizophrenia/ schizoaffective disorder Dependence abuse drug ( include alcohol benzodiazepine correspond 22.5 mg Oxazepam daily ) Diabetes Renal failure Smoking Major surgery within 4 week prior inclusion Previous Epotreatment Known allergy antibody Epo Present past malignancy Epilepsy epilepsy first degree family Diagnosis ( past present ) cardiovascular cerebrovascular disease Untreated sufficiently treat arterial hypertension ( `` therapyresistant hypertension '' ) Initial hematocrit &gt; 50 % ( male ) &gt; 48 % ( female ) Initial platelet count normal range laboratory Initial reticulocyte count norma range laboratory Past thromboembolic event thromboembolic event first degree family ( increase thromboembolic risk ) Contraindications prophylactic thrombosis treatment Myeloproliferative disorder , polycythemia Present immunosuppressive treatment cyclosporin Overweight ( BMI &gt; 30 ) body weight less 45 kg 95 kg Acute suicidal risk , present previous suicide attempt past 2 year Pregnancy breast feeding Women presently use contraceptive pill Sexually active woman child bear potential refuse use double barrier anticonception method Unwillingness inability comply requirement protocol include presence condition ( physical , mental , social ) likely affect subject 's ability comply protocol Present illness investigator 's opinion could affect patient 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Epo</keyword>
	<keyword>depression</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>cognition</keyword>
	<keyword>cognitive function</keyword>
	<keyword>antidepressant</keyword>
</DOC>